<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745053</url>
  </required_header>
  <id_info>
    <org_study_id>XLIMIT</org_study_id>
    <nct_id>NCT03745053</nct_id>
  </id_info>
  <brief_title>XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization</brief_title>
  <acronym>XLIMIT</acronym>
  <official_title>XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardionovum GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mediolanum Cardio Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardionovum GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess angiographic and clinical performance of Xlimus Drug
      Eluting Stent (DES) compared to Synergy Bioabsorbable Polymer Everolimus Eluting Stent in
      patients treated with percutaneous coronary angioplasty
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present clinical investigation is designed as a prospective, multicentre, international,
      randomized, open label, 2-arm parallel group, trial in patients undergoing Percutaneous
      Coronary Intervention (PCI) comparing Xlimus DES versus Synergy DES with respect to optical
      coherence tomography (OCT) derived measures at 6-month Follow Up (FU) and clinical events at
      12 months after procedure. A total of 180 patients will be recruited and randomized in the
      two groups in a 2:1 ratio. After index procedure, patients will be followed up by
      angiographic follow-up at 6 months and clinical follow-up at 12 months.The primary endpoint
      will be independently evaluated by the Core-Lab which will be blinded as to group assignment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized multi-centre controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The members of the Event Adjudication Committee and the Core Lab will be blinded to the patient assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent neointimal volume</measure>
    <time_frame>6-month follow-up</time_frame>
    <description>In-stent neointimal volume at 6-month follow-up, measured with OCT, as assessed by the Core-Lab. Neointimal volume will be calculated in all analyzed cross-sections and volumetric measurements and in stent neointimal volume will be compared in the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neointimal area</measure>
    <time_frame>6-month follow-up</time_frame>
    <description>Neointimal area calculated at the site of minimal lumen area measured with OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Target lesion failure</measure>
    <time_frame>12-months follow-up</time_frame>
    <description>composite of Cardiac death, target-vessel Myocardial infarction (MI) and clinically indicated target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencig Cardiac death</measure>
    <time_frame>12-months follow-up</time_frame>
    <description>Any death due to proximate cardiac cause (eg, MI, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Target-vessel Myocardial infarction</measure>
    <time_frame>12-months follow-up</time_frame>
    <description>any MI that, irrespective of the time after the index procedure, is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause. Type of acute MI is classified according to the Joint ESC/ACCF/AHA/ WHF Joint Task Force for the Universal Definition of Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Target-lesion revascularization</measure>
    <time_frame>12-months follow-up</time_frame>
    <description>repeat revascularization will be defined as any repeat PCI or new coronary artery bypass graft (CABG) surgery within the first year post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Stent thrombosis</measure>
    <time_frame>12-months follow-up</time_frame>
    <description>This is defined according to classification proposed by the Academic Research Consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Device success at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>deployment of the assigned stents without system failure or device-related complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Lesion success at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>attainment of &lt;50% residual stenosis of the target lesion using post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Procedural success at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>lesion success without the occurrence of major adverse cardiac event (MACE) during the hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>XLIMUS DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xlimus DES Implantation during coronary angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synergy DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synergy DES Implantation during coronary angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xlimus DES Implantation during coronary angioplasty</intervention_name>
    <description>Xlimus DES Implantation during coronary angioplasty</description>
    <arm_group_label>XLIMUS DES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergy DES Implantation during coronary angioplasty</intervention_name>
    <description>Synergy DES Implantation during coronary angioplasty</description>
    <arm_group_label>Synergy DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ageâ‰¥18

          2. Documented coronary artery disease (CAD): stable or unstable angina, Non-ST segment
             MI.

          3. PCI considered appropriate and feasible

          4. Culprit de novo lesion in a native coronary artery with significant stenosis (&gt;50% by
             visual estimate) eligible for implantation with either study stent (no limitation on
             the number of treated lesions, vessel and lesion length);

          5. Patient provides written informed consent

          6. Patient agrees to all required follow-up procedures and visits.

          7. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm

        Exclusion Criteria:

          1. The patient has a known hypersensitivity or contraindication to any of the following
             medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus or its derivatives,
             everolimus or structurally-related compounds, and/or contrast media (patients with
             documented sensitivity to contrast which can be effectively pre-medicated with
             steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true
             anaphylaxis to prior contrast media, however, should not be enrolled);

          2. Known hypersensitivity to L605 cobalt chromium, 316L stainless steel, platinum,
             chromium, iron, nickel or molybdenum;

          3. Known sensitivity to poly-lactic acid or poly(lactic-co-glycolic acid) polymer;

          4. Female of childbearing potential, unless a recent pregnancy test is negative, who
             possibly plan to become pregnant any time after enrolment into this study and not
             using adequate contraceptive methods;

          5. History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), or will refuse blood transfusions;

          6. Previous coronary intervention on target vessel in the 3-months prior to enrollment;

          7. Non-cardiac co-morbid conditions with life expectancy &lt;1 year or that may result in
             protocol non-compliance (per site investigator's medical judgment);

          8. Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period;

          9. Previously documented left ventricular ejection fraction (LVEF) &lt;30%;

         10. Evident cardiogenic shock before randomization;

         11. Patients with left main stem stenosis (&gt;50% by visual estimate);

         12. In-stent restenosis;

         13. ST-segment elevation MI;

         14. Chronic total occlusion/ heavily calcified lesions

         15. Culprit lesion to a Saphenous Vein graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Testa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadia Moffa, BSc</last_name>
    <phone>0039 026125141</phone>
    <email>moffa@mcr-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Cristina Jori, MD</last_name>
    <phone>0039 026125141</phone>
    <email>jori@mcr-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Testa, MD</last_name>
      <phone>00390252774987</phone>
      <email>luctes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luca Testa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Antoni GÃ³mez Hospital, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joan Antoni GÃ³mez Hospital, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Serra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antoni Serra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JosÃ© RaÃºl Moreno GÃ³mez, MD</last_name>
      <email>raulmorenog@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>JosÃ© RaÃºl Moreno GÃ³mez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Testa L, Pero G, Bollati M, Casenghi M, Popolo Rubbio A, Cuman M, Moreno R, Serra A, Gomez JA, Bedogni F. XLIMus drug eluting stent: A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial. Int J Cardiol Heart Vasc. 2019 Apr 28;23:100363. doi: 10.1016/j.ijcha.2019.100363. eCollection 2019 Jun.</citation>
    <PMID>31061876</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

